The UAB MS Center participates in clinical trials to evaluate the safety, efficacy and long-term impact and effectiveness of disease-modifying treatments for MS.
Focused areas of clinical study in the MS Center
- Immunological characteristics of MS patients
- Environmental and genetic risk factors, microbiomes and treatment adherence patterns in pediatric MS
- Effects of diet, exercise and wellness on MS
- Effect of rehabilitation on neuroplasticity and CNS remodeling
- Comorbidities and worsening MS
- Improving and developing measurement tools to track MS worsening
- Statistical analyses of MS prevalence in the U.S., existing and novel treatment effects, treatment comparison studies, impact of DMT discontinuation, & B-cell therapy in MS
Each of these areas of study holds the potential to make an immediate, significant difference in the daily lives of people with multiple sclerosis.
Taking part in a clinical trial
Clinical trials are studies in humans that evaluate whether new treatments are safe and effective. Trials occur in several phases: Early Phase 1, Phase 1, Phase 2, Phase 3 and Phase 4. As the phase number increases, more participants take part in the trial and researchers home in on the most effective doses of a new treatment. Early Phase 1 trials are done in very small groups and are primarily concerned with safety. Phase 3 and 4 trials, on the other hand, can involve hundreds or thousands of people.
To learn more about current MS clinical trials at UAB, please contact MS Center Research Coordinator, Kerry Howard, RN, MSCN at kdhoward@uabmc.edu
For questions regarding the TREAT MS Study, please contact Kendall Curtis, TREAT MS Study Coordinator and SHARP Liaison, at
205-975-2018.
Learn about the latest clinical trials available at UAB through ClinicalTrials.gov, a database maintained by the U.S. National Library of Medicine, at www.clinicaltrials.gov.